Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For The Management Of Fibromyalgia Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia.
Source: www.medicalnewstoday.comRib-X Pharmaceuticals Reports Positive Top-Line Results From Phase 2 Study Of Delafloxacin Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, announced positive topline results from a Phase 2 clinical trial with the intravenous form of its novel anionic quinolone antibiotic, delafloxacin (RX-3341).
Source: www.medicalnewstoday.comBeyond Seizure Control In The Treatment Of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM
Source: www.medicalnewstoday.comNew Medicine Recommendation By SMC Means Better Quality Of Life For Palliative Care Patients In Scotland The Scottish
Medicines Consortium (SMC) has today recommended Relistor (methylnaltrexone bromide) for use by the NHS in Scotland. Relistor is a new treatment developed to help overcome opioid-induced constipation, a common problem for many end-of-life patients receiving palliative care. Constipation is a particularly common side effect of opioid-based painkillers and can negatively impact on a patient's quality of life.
Source: www.medicalnewstoday.comSuperGen's PIM Kinase Inhibitor, SGI-1776, Effective In Pre-Clinical Models Of Acute Lymphoblastic Leukemia SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). This research was presented at the 50th Annual Meeting of the American Society of Hematology.
Source: www.medicalnewstoday.comCHMP Recommends Approval In The European Union (EU) For New Options For Patients With Certain Primary Brain Tumors Schering-Plough Corporation (NYSE: SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) has issued a positive opinion recommending approval of the intravenous (IV) formulation of TEMODAL(R) (temozolomide) as an alternative to the already approved oral form of temozolomide in the EU. The CHMP also has issued a positive opinion recommending approval of a sachet packaging presentation for TEMODAL Capsules.
Source: www.medicalnewstoday.comNew Medicine Recommendation By Scottish Medicines Consortium Means Better Quality Of Life For Palliative Care Patients In Scotland The Scottish
Medicines Consortium (SMC) has today recommended Relistor (methylnaltrexone bromide) for use by the NHS in Scotland. Relistor is a new treatment developed to help overcome opioid-induced constipation, a common problem for many end-of-life patients receiving palliative care. Constipation is a particularly common side effect of opioid-based painkillers and can negatively impact on a patient's quality of life.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
